Parsippany, New Jersey, United States Daiichi Sankyo appeared to be the Corporate Investor, which was created in 2005. The main office of represented Corporate Investor is situated in the Parsippany. The venture was found in North America in United States.
This organization was formed by Mike Rothe.
The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2012. The increased amount of exits for fund were in 2014. The usual things for fund are deals in the range of 50 - 100 millions dollars.
Among the most successful fund investment fields, there are Biotechnology, Therapeutics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Coherus Biosciences.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Daiichi Sankyo, startups are often financed by Medpace, Helix Ventures. The meaningful sponsors for the fund in investment in the same round are Medpace, Lilly Ventures, Helix Ventures. In the next rounds fund is usually obtained by Helix Ventures, Vivo Capital, Viva Capital Advisors.
Related Funds
| Fund Name | Location |
| Actel | California, San Jose, United States |
| Biotech Alliances International | - |
| BrightHouse | California, Santa Monica, United States |
| Bupa | England, London, United Kingdom |
| Chengdu Commercial and Industrial Enterprise Management Center | Chengdu, China, Sichuan |
| Critical Content | California, United States, West Hollywood |
| Crosspoint Venture Partners | California, Redwood City, United States |
| EXCEL Communications | Sterling, United States, Virginia |
| FBR CoMotion Venture Capital | Seattle, United States, Washington |
| Genacast Ventures | New York, New York, United States |
| Huiyi Xinxi | Beijing, China, Fengtai |
| Keesing Media Group | Amsterdam, Noord-Holland, The Netherlands |
| Lightblue Technology | Japan, Tokyo |
| Naver Corporation | Kyonggi-do, Seongnam, South Korea |
| New England Patriots | Foxboro, Massachusetts, United States |
| NSRCEL, IIM, Bangalore | - |
| PiPEDO HD | Japan, Tokyo |
| Schibsted Growth | Norway, Oslo |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cuorips, Inc. | $910K | 07 Aug 2017 | Sapporo, Hokkaido Prefecture, Japan | ||
Orphan Disease Treatment Institute | $1M | 14 Feb 2013 | Chiyoda, Japan | ||
Coherus Biosciences | $61M | 01 Jan 2012 | Redwood City, California, United States | ||
SymBio Pharmaceuticals | 18 Oct 2005 | Chiyoda, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cuorips, Inc. | $910K | 07 Aug 2017 | Sapporo, Hokkaido Prefecture, Japan | ||
Orphan Disease Treatment Institute | $1M | 14 Feb 2013 | Chiyoda, Japan | ||
Coherus Biosciences | $61M | 01 Jan 2012 | Redwood City, California, United States | ||
SymBio Pharmaceuticals | 18 Oct 2005 | Chiyoda, Japan |
